GREAT WESTERN HOSPITALS NHS FOUNDATION TRUST. Formulary Working Group 2.00pm 19 th January 2017 Radiology Room, Ground Floor, GWH
|
|
- Paul Cook
- 5 years ago
- Views:
Transcription
1 Formulary Working Group 2.00pm 19 th January 2017 Radiology Room, Ground Floor, GWH The 3T s Formulary Swindon CCG & Wiltshire CCG Great Western Hospitals NHS Foundation Trust (In collaboration with Avon and Wiltshire Mental Health Partnership and Oxford Health NHS Foundation Trust Attendees: Dr Francis Campbell (FC) (chair) Magda Blahut-Zugaj (MB) Lisa King () Dr Rachel Hobson (RH) Dr Anna Collings (AC) Surinder Bassan (SB) Terri Turner (TT) Mair Robinson (MR) Paul Clarke (PC) (mins) Harpreet Rajput (HR) (from 3pm) Apologies Dr Sherlie Arulanandam (SA) Dr Peter Mack (FC) GP representative, Swindon GWH Consultant representative Formulary Pharmacist, GWH Formulary Pharmacist, Wiltshire CCG GP representative, Wiltshire CCG Director of Pharmacy and Medicines Optimisation, GWH Pharmacist AWP Medicines Management Pharmacist, Wiltshire CCG Pharmaceutical Advisor, Swindon CCG Deputy Director of Pharmacy and Medicines Optimisation, GWH Consultant Psychiatrist, AWP GP Representative, Swindon Agenda Item 1 APOLOGIES Description Action by whom 2 3 MINUTES OF LAST MEETING Minutes of the last meeting with minor amendments were agreed as accurate. to amend and upload pdf version to formulary website and forward to TPC for information. MATTERS ARISING Please see action tracker for progress on actions from last meeting and plan to expedite matters arising. Of particular note: GWH Dermatology Meeting Notes from the meeting on were shared. With a few exceptions, GWH dermatologists were happy with the proposed changes to the first line emollients. However TVN opinion is that an emollient containing is glycerine is required. RH will check the evidence for this and meet with at SFT dermatologists before finalising the emollient guidance and bringing back to the revised guidance to the group. Valproic Acid Shared Care Agreement. The group was happy, that now that new guidance has been agreed, there is no longer a need for a Valproic acid SCA. will amend formulary accordingly. Linaclotide. The gastroenterologists have stated they do not have the capacity to follow up patients 4 weeks after initiation. The group proposed GPs could make the decision about whether the drug was working and should be continued if specific criteria for stopping were included in the discharge letter sent to the GP (this letter is also copied to the patient). to work with the gastroenterologists on the content of the letter. ALL RH T:\Pharmacy\3 T's Formulary\FWG Meetings\FWG Minutes\Mins_2017\FWG_Minutes_19 January 2017.Doc Page 1 of 5
2 4 4.1 CHAPTER/SECTION UPDATES High strength insulins It was noted that there has already been a safety incident in a neighbouring CCG where the contents were removed from a high strength insulin pen using an insulin syringe, in order that the nurse could use a safety needle rather than a pen needle. RH tabled a document outlining the risks and befits of the high strength insulins Toujeo and Degludec 200units/ml. Toujeo It was noted that 2 out of 3 RCTs had shown a statistically significant reduction in confirmed or severe nocturnal hypoglycaemia in Type 2 diabetics with Toujeo compared to Lantus, equating to approx 1 less event per person per year. However, it was also noted that this had not been demonstrated for Type 1 diabetics; that clinical trials had shown no difference in pain at injection site with Toujeo compared to Lantus despite smaller injection volume; that EPAR states the more gradual glucose lowering with Toujeo compared to Lantus did not translate to important advantages; that NICE evidence summary states that limitation of device to 80 units per injection negates the most obvious advantage of Toujeo. Degludec 200untis/ml It was noted that 2RCTs had shown a statistically significant reduction in nocturnal hypoglycaemia in Type 1 diabetics of between 1.4 and 4 episodes per patient per year; and that there were reductions of about 2.5 episodes of overall hypoglycaemia, 0.5 episodes of nocturnal hypoglycaemia, and 2.1 episodes of daytime hypoglycaemia per patient per year of treatment in BEGIN Basal-Bolus Type 2; and reductions of 0.14 episodes of nocturnal hypoglycaemia in BEGIN Once Long (Type 2). However, it was noted that Degludec is also available in 100unit/ml strength which introduces risk; that clinical trials had shown similar numbers of patients reporting injection site reactions with Degludec as with Lantus, despite smaller injection volume with Degludec 200unit/ml; and that EPAR had highlighted that clinical data was unable to confirm if lower pharmacodynamic variability translates into more stable glucose profiles in clinical practice. On balance, it was agreed that only the high strength degludec would be included on the formulary with the specific criteria for use being reducing incidents of hypoglycaemia, reducing hospital admissions and reduced HbA1C. The formulary entry must state that the high strength insulin is for self-administration only, to prevent misguided attempts by health care professionals to remove insulin from the pen in order to use a safety needle. The CCG pharmacists agreed to ensure their point of prescribing software was updated to alert prescribers that they have selected a high- strength insulin. It was agreed that Toujeo would not be added and Humalog 200 would be removed from the formulary. and MB to feedback to Dr Vaks. PC/RH /MB It was noted that a trial making a direct comparison of Toujeo and high strength Degludec is due to be published in the autumn and this decision will be reviewed when the trial is published. T:\Pharmacy\3 T's Formulary\FWG Meetings\FWG Minutes\Mins_2017\FWG_Minutes_19 January 2017.Doc Page 2 of 5
3 Wiltshire Blood Glucose Monitoring Guidance This guidance is specific to Wiltshire CCG, but it was agreed that it should be published on the 3Ts formulary website. Swindon CCG also has specific guidance which should also be published on the 3Ts website. Esmya for uterine fibroids The Devon guidance, and the suggestion that in menopausal patients Esmya could potentially spare surgery, was noted. Wiltshire are reviewing their commissioning policy and the formulary status of Esmya may need to be reviewed as a result. to advise GWH Gynaecology team of current formulary status of Esmya. Drugs affecting QTc interval The BMJ paper on QT interval and drug therapy was discussed and it was agreed the list of drugs along with advice on how to minimise the risks of these drugs in clinical practice should be summarised as a separated piece of guidance. PC/ PC 5 NEW DRUG Update UKMI New Drugs Online Newsletters for November 2016 & December 2016 were noted. to approach GWH gastroenterology team about developing mab treatment pathway New Drug Requests Fosfomycin IV infusion. It was agreed to add this formulation to the formulary as a red drug for use on microbiological advice only. Modulen IBD This was not added to the formulary. The group felt that the case for use in adults and maintenance therapy was not made. Also, that given that the supplement is used so infrequently and for limited courses, a better alternative would be for the tertiary care centre to prescribe for the entire course. /PC to feedback. NICE NICE TAs TA 427 Pomalidomide for multiple myeloma previously treated with lenalidomide and Bortezomib TA 428 Pembrolizumab for treating PDL1-positive non-small-cell lung cancer after chemotherapy TA 421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy TA 422 Crizotinib for previously treated anaplastic lymphoma kinasepositive advanced non-small-cell lung cancer /PC T:\Pharmacy\3 T's Formulary\FWG Meetings\FWG Minutes\Mins_2017\FWG_Minutes_19 January 2017.Doc Page 3 of 5
4 TA 423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens TA 424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer TA 425 Dasatinib, nilotinib and high-dose imatinib for treating imatinibresistant or intolerant chronic myeloid leukaemia Commissioned by NHS England & covered by TVCN TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia TA 420 Ticagrelor for preventing atherothrombotic events after myocardial infarction This will have a significant impact on primary care prescribing, and the existing antiplatelet guidance will need updating to reflect the guidance. It was agreed to invite a cardiologist discuss this guidance at the next meeting. TA 288 Dapagliflozin in combination therapy for treating type 2 diabetes The formulary will be updated to reflect this guidance. TA 417 Nivolumab for previously treated advanced renal cell carcinoma TA 418 Dapagliflozin in triple therapy for treating type 2 diabetes The formulary will be updated to reflect this guidance. TA 410 Apremilast for treating moderate to severe plaque psoriasis The formulary will be updated to reflect this guidance. It was noted that any patient taking the drug currently funded by the drug company would need to continue with this funding route unless they comply with the conditions laid out in the TA. 8 MHRA Drug Safety Updates November & December 2016 These were noted. Links will be made to the relevant formulary drugs AOB Braltus Zonda. It was agreed this would be added to the formulary and that the suggestions from the respiratory consultants around the capsule colour and possible taste on inhalation would be included in any primary care switch letters. The COPD guidance will also be updated to reflect this. HIV Drugs. tabled two additional HIV drugs that need to be included on the formulary. As these are funded by NHS England the group was happy for these to be added. /RH/ PC T:\Pharmacy\3 T's Formulary\FWG Meetings\FWG Minutes\Mins_2017\FWG_Minutes_19 January 2017.Doc Page 4 of 5
5 Date, time & venue of next FWG Meeting: 2.00pm. 16 th March Radiology Room, Ground Floor, GWH. Future Meetings: Date Start Finish Room Time Time 18/05/ :00 17:00 Seminar Room 1, The Academy, GWH. 20/07/ :00 17:00 Seminar Room 1, The Academy, GWH. 21/09/ :00 17:00 Radiology Room, Ground Floor, GWH. 16/11/ :00 17:00 Seminar Room 1, The Academy, GWH. Agreed as an Accurate Record: Chair: T:\Pharmacy\3 T's Formulary\FWG Meetings\FWG Minutes\Mins_2017\FWG_Minutes_19 January 2017.Doc Page 5 of 5
GREAT WESTERN HOSPITALS NHS FOUNDATION TRUST. Formulary Working Group 2.00pm 20 th September 2018 The ALIS Room, The Academy, GWH
Formulary Working Group 2.00pm 20 th September 2018 The ALIS Room, The Academy, GWH The 3T s Formulary Swindon CCG & Wiltshire CCG Great Western Hospitals NHS Foundation Trust (In collaboration with Avon
More informationGREAT WESTERN HOSPITALS NHS FOUNDATION TRUST
The 3T s Formulary NHS Swindon NHS Wiltshire Great Western Hospitals NHS Foundation Trust (In collaboration with Avon and Wiltshire Mental Health Partnership and Oxford Health NHS Foundation Trust) Attendees:
More informationGREAT WESTERN HOSPITALS NHS FOUNDATION TRUST
Attendees: Dr Ravi Chinthapalli (RC) (chair) Katherine Watkinson () (mins) Dr Rachel Hobson (RH) Paul Clarke (PC) Lisa King (LK) Formulary Working Group 17 th October 2013 1400 1510 Liden Meeting Room,
More informationNorth of Tyne & Gateshead Area Prescribing Committee DECISION SUMMAY North of Tyne & Gateshead Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting
More informationGREAT WESTERN HOSPITALS NHS FOUNDATION TRUST. Formulary Working Group 2.30pm 19 th June 2014 Seminar Room 7, The Academy, GWH
Formulary Working Group 2.30pm 19 th June 2014 Seminar Room 7, The Academy, GWH The 3T s Formulary Swindon CCG & Wiltshire CCG Great Western Hospitals NHS Foundation Trust (In collaboration with Avon and
More informationSummary of Main Points from the Meeting held on Monday 13 th February 2017
Summary of Main Points from the Meeting held on Monday 13 th February 2017 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the December 2016 Medicines Group meeting were
More informationNotes from the Area Prescribing Committee Meeting held on Friday 17 th February 2017 Room 5, Education Centre, E level, Queen Alexandra Hospital
NHS Portsmouth CCG South Eastern Hampshire CCG Fareham and Gosport CCG Portsmouth Hospitals NHS Trust Southern Health NHS Foundation Trust Solent NHS Trust Notes from the Area Prescribing Committee Meeting
More informationNICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017
NICE TECHNOLOGY PPRISL MEDICINES REPORT St George s Healthcare NHS Trust key for medicine-related NICE Technology ppraisals. has been approved by the Drugs and Therapeutics Committee as recommended within
More informationSummary of Main Points from the Meeting held on Monday 12 th December 2016
Summary of Main Points from the Meeting held on Monday 12 th December 2016 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the November 2016 Medicines Group meeting were
More informationEAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD MINUTES OF THE MEETING HELD ON WEDNESDAY 15 th JUNE 2016 AT 12.30pm IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationFreeStyle Libre for glucose monitoring: Interim Position Statement for GPs & Patient FAQ
North Central London Joint Formulary Committee FreeStyle Libre for glucose monitoring: Interim Position Statement for GPs & Patient FAQ GPs should not prescribe FreeStyle Libre sensors on the NHS until
More informationMinutes of Rotherham Medicines Optimisation Group (RMOG)
Minutes of Rotherham Medicines Optimisation Group (RMOG) Date/time: Venue: Chair: Minutes: Wednesday 4 th October, 1pm 3pm Pharmacy Seminar Room, A level, Rotherham Hospital Osman Chohan, Chief Pharmacist
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationPolicy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group
BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical
More informationACORN patient participation group Minutes of meeting held on Thursday 20 November South Northumberland Cricket Club 5:30pm 7:30pm
ACORN patient participation group Minutes of meeting held on Thursday 20 November South Northumberland Cricket Club 5:30pm 7:30pm Present: Name Initials Gill Clancy (Chair) GC Brunton Park Health Centre
More informationChapter 8 Malignant Disease and Immunosuppression
Chapter 8 page number 1 Chapter 8 Malignant Disease and Immunosuppression First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions)
More informationDraft Minutes. 15 th September 2015, 12:30-2:30 pm Pharmacy Dept. CMFT
Draft Minutes 15 th September 2015, 12:30-2:30 pm Pharmacy Dept. CMFT Present: Elizabeth Adcock (EA) Medicines Information Pharmacist, PAHT Jennifer Bartlett (JB) Senior Medicines Management Pharmacist
More informationEAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD IN SEMINAR ROOM 7, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD MINUTES OF THE MEETING HELD ON WEDNESDAY 15 th FEBRUARY 2017 AT 12.30pm IN SEMINAR ROOM 7, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
More informationNorth of Tyne Area Prescribing Committee DECISION SUMMARY North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 11 No 12, September 2017 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationSummary of Main Points from the Meeting held on Monday 9 th April 2018
Summary of Main Points from the Meeting held on Monday 9 th April 2018 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the 12 th March 2018 Medicines Group meeting were
More informationPriorities Advisory Committee
Insulin degludec (Tresiba ) PAC - Insulin degludec (Tresiba ) 2.1 The East of England Priorities Advisory Committee A function of GUIDANCE STATEMENT PAC Recommendations 1. Insulin degludec is NOT recommended
More informationESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.
ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of
More informationSunderland Diabetes Network - Recommendations for safe prescribing of insulin.
Sunderland Diabetes Network - Recommendations for safe prescribing of insulin. Note: High strength insulins and biosimilar insulins are for specialist initiation only. They should not be initiated in primary
More informationPlacename CCG. Policies for the Commissioning of Healthcare
Placename CCG Policies for the Commissioning of Healthcare Policy for the funding of insulin pumps and continuous glucose monitoring devices for patients with diabetes 1 Introduction 1.1 This document
More informationNHS Leeds CCG. Policy for the Funding of Flash Glucose Monitoring (FlashGM) in Paediatrics and Adults
NHS Leeds CCG Policy for the Funding of Flash Glucose Monitoring (FlashGM) in Paediatrics and Adults Produced by: Jo Alldred, Medicines Effectiveness Lead, NHS Leeds CCG Dr Bryan Power, Long Term Conditions
More informationEAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD MINUTES OF THE MEETING HELD ON WEDNESDAY 15 th NOVEMBER 2017 AT 12.30pm IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
More informationCommissioning Statement
Commissioning Statement Treatment/ device For the treatment of Commissioning position Flash Glucose Monitoring Systems (including Freestyle Libre ) Monitoring glucose levels in adults and children over
More informationPegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440
This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks
More informationSOMERSET PRESCRIBING FORUM
SOMERSET PRESCRIBING FORUM Minutes of the meeting held at Wynford House, Yeovil, on Wednesday 14 November 2012 Present Position Initials Chair, Drug & Therapeutics Committee, Taunton & Somerset NHS Foundation
More information29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationSunderland Diabetes Network - Recommendations for safe prescribing of insulin.
Sunderland Diabetes Network - Recommendations for safe prescribing of insulin. Note: High strength insulins and biosimilar insulins are for specialist initiation only. They should not be initiated in primary
More informationNHS GG&C Introduction of Freestyle Libre flash glucose monitoring system
NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system The Freestyle Libre flash glucose monitoring system is a sensor based, factory-calibrated system that measures interstitial fluid
More informationCommissioning Policy
Commissioning Policy Abbott FreeStyle Libre Flash Glucose Monitoring System Individual Funding Request Date Adopted: 09 September 2018 Version: 1819.1.02 Title of document: Authors job title(s): Document
More informationrequesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group
requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationShort-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
More informationEvidence review for Surrey Prescribing Clinical Network SUMMARY
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Surrey Prescribing Clinical Network Medicine
More informationADVANCE PREPARATION OF INSULIN FOR PATIENTS TO ADMINISTER AT HOME
STANDARD OPERATING PROCEDURE ADVANCE PREPARATION OF INSULIN FOR PATIENTS TO ADMINISTER AT HOME First Issued July 08 Issue Version Two Purpose of Issue/Description of Change Planned Review Date To promote
More informationSummary of Main Points from the Meeting held on Monday 13 th March 2017
Summary of Main Points from the Meeting held on Monday 13 th March 2017 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the February 2017 Medicines Group meeting were
More informationBrighton Area Prescribing Committee Minutes Date: Tuesday 24 th January 2017 Time: 2-5pm Location: Room G90, Hove Town Hall, Norton Road, Hove
Brighton Area Prescribing Committee Minutes Date: Tuesday 24 th January 2017 Time: 2-5pm Location: Room G90, Hove Town Hall, Norton Road, Hove Brighton and Hove CCG High Weald Lewes Havens CCG Members:
More informationOptimising Insulin Pen Needles
Optimising Insulin Pen Needles Following a review of insulin pen needles NHS Telford and Wrekin CCG now recommends the use of GlucoRx FinePoint Pen Needles. GlucoRx FinePoint Pen Needles are a high quality
More informationSOMATROPIN ( Genotropin, Humatrope, Norditropin,
Shared Care Guidelines DRUG: SOMATROPIN ( Genotropin, Humatrope, Norditropin, Saizen and Omnitrope ) (Adults) Introduction: Indication: Growth hormone deficiency in adults Dosage & administration: 150-300
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA151 Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus This guidance was issued in
More informationChelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group
Summary of Main Points from the Meeting held on Monday 11 th July 2016 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the June 2016 Medicines Group meeting were approved
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationMinutes of Rotherham Medicines Optimisation Group (RMOG)
Minutes of Rotherham Medicines Optimisation Group (RMOG) Date/time: Wednesday 3 August, 1pm 3pm Venue: Board Room Chair (Interim): Dr Wareham Minutes: Jill Brown Escalations to Clinical Governance Committee
More informationPRESCRIPTION PAD. The Newsletter of the Cumbria Area Prescribing Committee. February 2012 No. 18. Click here to find more. News from the MHRA
PRESCRIPTION PAD The Newsletter of the Cumbria Area Prescribing Committee February 2012 No. 18 Click here to find more Clinical policy and Formulary news Lothian changes Targeted Medication Use Reviews
More informationMeeting of the SWAG Network Haematology SSG
Meeting of the SWAG Network Haematology SSG Tuesday 21 st November 2017, 14:00-16:30 Penny Brohn Cancer Care, Chapel Pill Lane, Pill, Bristol, BS20 0HH This meeting was sponsored by Celgene and Novartis
More informationEssential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community
E088 Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community Patient s name: DOB NHS Number Patient s address: Consultant Note: Shared care agreement sets out a
More informationPolicy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus Version No. Changes Made Version of July 2018 V0.5 Changes made to the policy following patient engagement including: - the
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 10 th May 2011
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 10 th May 2011 Summary Points Shared care updates Acetylcholinesterase inhibitors Modafanil for narcolepsy Riluzole
More informationBuprenorphine used in the treatment of opioid dependence: availability and price
7 th floor Wellington House 133 155 Waterloo Road London SE1 8UG 24 October 2018 Gateway number: L2018-443 Dear Director of Public Health, Buprenorphine used in the treatment of opioid dependence: availability
More informationPEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate Day 1 Pembrolizumab 2mg/kg IV Infusion 100mL 0.9% Sodium Chloride* Or 100mL 5% Glucose* *Final concentration must be between 1 to 10mg/mL Over
More information9 Diabetes care. Back to contents
Back to contents Diabetes is a major risk factor for the development of peripheral vascular disease and 349/628 (55.6%) of the patients in this study had diabetes. Hospital inpatients with diabetes are
More informationNew Medicine Assessment
New Medicine Assessment Insulin Glargine 300 units/ml (Toujeo ) Treatment of type 2 diabetes mellitus in adults Recommendation: Amber 0 Insulin glargine 300 units/ml (Toujeo ) is recommended as an option
More informationMinutes. 21 st July 2015, 12:30-2:30 pm Pharmacy Dept. CMFT
Minutes 21 st July 2015, 12:30-2:30 pm Pharmacy Dept. CMFT Present: Elizabeth Adcock (formerly Craig) (EA) Medicines Information Pharmacist, PAHT Jennifer Bartlett (JB) Senior Medicines Management Pharmacist
More informationTAYSIDE PRESCRIBER. ADTC Supplement No. 20
TAYSIDE PRESCRIBER ADTC Supplement No. 20 October 2002 In this issue: Annual Report Tayside Area Prescribing Guide Scottish Medicines Consortium (SMC) update Extending Independent Nurse Prescribing Symptomatic
More informationTechnology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531
Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
National Institute for Health and Care Excellence Single Technology Appraisal (STA) Nivolumab for treating advanced (unresectable or metastatic) melanoma At the scoping consultation stage, the scopes for
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationNational Diabetes Inpatient Audit (NaDIA) 2016
National Diabetes Inpatient Audit (NaDIA) 2016 DIABETES A summary report for people with diabetes and anyone interested in the quality of care for people with diabetes when they stay in hospital. Based
More informationMinutes. 19 th May 2015, 12:30-2:30 pm Pharmacy Dept. CMFT
Present: Minutes 19 th May 2015, 12:30-2:30 pm Pharmacy Dept. CMFT Elizabeth Adcock (formerly Craig) (EA) Medicines Information Pharmacist, PAHT Elizabeth Arkell (EA), Associate Director of Pharmacy, UHSM
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationATEZOLIZUMAB (TECENTRIQ ) in urothelial carcinoma
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationSPAGG. Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation
SPAGG Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation This sheet is to accompany all documentation agreed by SPAGG. This will assist maintenance of the guidelines as
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 8 May 2012
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 8 May 2012 Summary Points Traffic lights Drug Pro D3 Fultium Rifaxamin for traveller s diarrhoea Rifaxamin for
More informationConsultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off
Policy For The Adjustment Of Insulin Injections By Paediatric Diabetes Specialist Nurses/Community Paediatric Nurses Diabetes Working With Children Within NHS Grampian Co-ordinators: Lead Paediatric Diabetes
More information04 September 2017 Page 1 of 6
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Type 2 diabetes: the management of type 2 diabetes (update)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Type 2 diabetes: the management of type 2 diabetes (update) 1.1 Short title Type 2 diabetes (update) 2 Background a) The National
More informationManaging Hyperglycaemia in Acute (Adult) Inpatients Requiring Enteral Feeding Guidelines
Document Control Title Managing Hyperglycaemia in Acute (Adult) Inpatients Requiring Author Author s job title Specialist Nurse Consultant Physician Department Directorate Unscheduled Care Version Date
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationHaematology Regional Group Meeting Monday 18 th October 2010, Antrim Hospital
Haematology Regional Group Meeting Monday 18 th October 2010, Antrim Hospital In attendance: Dr Anne Kyle Clinical Lead Ms Sarah Taggart Ms Caroline McCaughey Ms Margaret Michael Dr Robert Cuthbert Ms
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) JAPC Briefing FreeStyle Libre
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) JAPC Briefing FreeStyle Libre JAPC has classified Freestyle Libre as BROWN after diabetes consultant/specialist initiation within a Derbyshire diabetes
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationFOWEY RIVER PRACTICE PATIENT PARTICIPATION GROUP MEETING MINUTES OF THE MEETING WEDNESDAY 14 TH OCTOBER 2015 PAR 6PM
FOWEY RIVER PRACTICE PATIENT PARTICIPATION GROUP MEETING MINUTES OF THE MEETING WEDNESDAY 14 TH OCTOBER 2015 PAR 6PM PRESENT Chair, BL, Anne B, Annette B, Amanda Bone, RD, VD, SG, EG, MK, ChintyP, Christine
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationATEZOLIZUMAB (TECENTRIQ )
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationColorectal Cancer Pathway Clinical Subgroup Tuesday 4 th September pm 4 pm CTCCU Seminar Room UHSM
Manchester Cancer Colorectal Cancer Pathway Clinical Subgroup Tuesday 4 th September2014 2 pm 4 pm CTCCU Seminar Room UHSM Attendance Sarah Duff Michael Braun David Bisset Mohammed Sadat Deborah Hitchen
More informationNORTH WALES NHS TRUST GLAN CLWYD HOSPITAL (CENTRAL AREA)
NORTH WALES NHS TRUST GLAN CLWYD HOSPITAL (CENTRAL AREA) MINUTES OF THE CONWY & DENBIGHSHIRE DRUG & THERAPEUTICS COMMITTEE MEETING HELD IN THE RON & MARGARET SMITH SEMINAR ROOM, NORTH WALES CANCER TREATMENT
More informationBuccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.
Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment
More informationMedicines Optimisation Team Standard Operating procedure for Alogliptin Audit:
Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit: To review type 2 diabetic patients prescribed dipedtidylpeptidase-4 (DPP-4) inhibitors (linagliptin (Trajenta, saxagliptin
More informationPRIMARY CARE CO-COMMISSIONING COMMITTEE. 9 June 2015
Agenda Item No. 9 Part 1 X Part 2 PRIMARY CARE CO-COMMISSIONING COMMITTEE 9 June 2015 Title of Report National Flu Plan Winter 2015/16 Requirement Summary and Trafford CCG Option Appraisal Purpose of the
More informationClinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents
Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationWestern Bay Together for Mental Health Local Partnership Board
Western Bay Together for Mental Health Local Partnership Board s of the meeting held on 8 th September 2016 In the Boardroom ABMU Health Board Headquarters 2.00pm. Present: Hazel Powell Lily Bidmead Dawn
More informationPHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS
PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS The benefits of prefilled syringes for palliative care from the hospital pharmacy service In
More informationPaliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016)
Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016) 1. Key Points 1.1 Paliperidone palmitate 3-monthly long-acting
More informationNICE update. Paul Chrisp, Programme Director, Medicines and Prescribing Centre
NICE update Paul Chrisp, Programme Director, Medicines and Prescribing Centre Outline NICE offers a comprehensive suite of guidance, advice and support for delivering quality, safety and efficiency in
More informationInsulin Management. By Susan Henry Diabetes Specialist Nurse
Insulin Management By Susan Henry Diabetes Specialist Nurse The Discovery of Insulin - 1921 - Banting & Best University Of Toronto Discovered hormone insulin in pancreatic extract of dog - Marjorie the
More informationGENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY
GENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY First issued by/date Issue Version Purpose of Issue/Description of Change Planned Review Date August 2018 1.0 Promoting generic prescribing whenever
More informationEPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST NEW DRUG AND INTERFACE GROUP
EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST NEW DRUG AND INTERFACE GROUP MINUTES OF THE MEETING HELD ON WEDNESDAY 8 th February 2017 IN UNDERGRADUATE SEMINAR ROOM 3, FERGUSON HOUSE, ST HELIER HOSPITAL
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationLothian RESPIRATORY MCN CORE GROUP Wednesday, 19 th March 2.00pm to 4.00 pm The Chancellor s Building Seminar room 6, RIE
Lothian RESPIRATORY MCN CORE GROUP Wednesday, 19 th March 2.00pm to 4.00 pm The Chancellor s Building Seminar room 6, RIE Present: Dr Ninian Hewitt - GP and Lead Clinician, Respiratory MCN (Chair) Ms Alyson
More information